February 06, 2025
Press releases
Latest news
February 05, 2025
Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Reductions in CSF-HS
Read more
January 12, 2025
Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones
Read more
January 06, 2025
Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Read more
December 20, 2024
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Read more
December 19, 2024
Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome
Read more
December 19, 2024
Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
Read more
November 20, 2024
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Read more
Displaying 1 - 10 of 10